Pulse Biosciences (PLSE) EBITDA Margin (2021 - 2025)

Pulse Biosciences' EBITDA Margin history runs 3 years deep, the most recent figure standing at 22540.7% for Q3 2025.

• In Q3 2025, EBITDA Margin changed N/A year-over-year to 22540.7%; the TTM figure through Sep 2025 stood at 86898.84% (changed N/A YoY), while the FY2022 annual figure was 8357.86%, down 386851.0% from the prior year.
• EBITDA Margin was 22540.7% for Q3 2025 at Pulse Biosciences, down from 102188.89% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 102188.89% in Q4 2022 to a low of 22540.7% in Q3 2025.
• Historically, EBITDA Margin has averaged 11129.64% across 3 years, with a median of 3189.23% in 2021.
• Biggest YoY gain for EBITDA Margin was 10401543 bps in 2022; the steepest drop was 10401543 bps in 2022.
• A 3-year view of EBITDA Margin shows it stood at 1826.54% in 2021, then surged by 5695 bps to 102188.89% in 2022, then sank by 122 bps to 22540.7% in 2025.
• The last three EBITDA Margin figures came in at 22540.7% (Q3 2025), 102188.89% (Q4 2022), and 4665.33% (Q2 2022), per Business Quant data.